We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MQ:NASDAQMarqeta, Inc. Analysis

Data as of 2026-04-18 - not real-time

$4.39

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Marqeta’s stock is trading at $4.39, comfortably above its 20‑day (4.075) and 50‑day (4.060) simple moving averages but still below the 200‑day average (4.931), suggesting short‑term bullish momentum within a longer‑term downtrend. The RSI of 63.8 and a bullish MACD histogram (+0.036) reinforce this near‑term upside, while the price sits near the technical resistance of $4.42 and above the support level of $3.82. Revenue is expanding at a brisk 26.7% year‑over‑year with a robust 70% gross margin, yet operating margins remain negative (‑7.6%) and the company posts a modest loss per share (‑$0.03). Strong cash balances ($771.9 M) and positive free cash flow ($138.9 M) offset the low debt load, but the forward P/E of 62.7 versus the industry average of 36.7 signals an overvalued valuation. Analysts forecast a modest upside of ~17% (target median $5.00) and the DCF model implies a fair value near $13.4, creating a wide valuation spread. Upcoming Q1 2026 earnings on May 5, an insider sale of 5,055 shares, and JPMorgan’s recent “overweight” rating with a $6 price target add short‑term catalysts that could swing sentiment in this high‑volatility (38.8% 30‑day) environment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and RSI indicate near‑term momentum
  • Price approaching technical resistance at $4.42
  • Upcoming Q1 earnings release adds catalyst risk

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Strong revenue growth and high gross margin
  • Positive free cash flow and ample cash reserves
  • Analyst target median price of $5.00 suggests ~17% upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Persistent operating losses and high forward P/E
  • Competitive fintech landscape and regulatory exposure
  • Need for sustained profitability to justify valuation

Key Metrics & Analysis

Financial Health

Revenue Growth26.70%
Profit Margin-2.23%
P/E Ratio62.7
ROE-1.51%
ROA-1.73%
Debt/Equity1.12
P/B Ratio2.5
Op. Cash Flow$162.6M
Free Cash Flow$139.0M
Industry P/E36.7

Technical Analysis

TrendNeutral
RSI63.8
Support$3.82
Resistance$4.42
MA 20$4.08
MA 50$4.06
MA 200$4.93
MACDBullish
VolumeStable
Fear & Greed Index90.21

Valuation

Fair Value$13.41
Target Price$5.16
Upside/Downside17.43%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.89
Volatility38.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.